0 Items
Select Page

MERS Coronavirus

Middle East respiratory syndrome-related coronavirus (MERS-CoV) was first reported in 2012 after genome sequencing of a virus isolated from human sputum samples taken from a patient with flu-like symptoms and it has since spread rapidly. Since 2012, MERS-CoV has caused over 800 deaths in 27 countries with Saudi Arabia being the most affected. It is an acute respiratory disease and often leads to pneumonia and renal failure, very similar to severe acute respiratory syndrome (SARS) caused by another coronavirus, SARS-CoV.

MERS-CoV is one of several viruses identified by WHO as a likely cause of a future epidemic and is listed for urgent research and development. The high case fatality rate, vaguely defined epidemiology, and absence of prophylactic or therapeutic measures against this novel virus have created an urgent need for an effective vaccine should an outbreak expand to pandemic proportions.

MERS Coronavirus Background

MERS-CoV was first reported in 2012 after genome sequencing of a virus isolated from human sputum samples taken from a patient with flu-like symptoms and it has since spread rapidly (Al-Amri et al., 2017). Since 2012, MERS-CoV has caused over 800 deaths in 27 countries with Saudi Arabia being the most affected (Hashem et al., 2019). It is an acute respiratory disease and often leads to pneumonia and renal failure, very similar to severe acute respiratory syndrome (SARS) caused by another coronavirus, SARS-CoV.

Like SARS-CoV, MERS-CoV is a zoonotic virus transmitted from animals to humans. The evolutionary origins of MERS-CoV are unknown but evidence suggests that insectivorous bats are likely to be the original source (Anthony et al., 2017). MERS-CoV and its neutralizing antibodies have also been detected in dromedary camels, which act as a reservoir host (Reusken et al., 2013) and both bat-to-human and camel-to-human transmission is possible.

MERS-CoV is one of several viruses identified by WHO as a likely cause of a future epidemic and is listed for urgent research and development. The high case fatality rate, vaguely defined epidemiology, and absence of prophylactic or therapeutic measures against this novel virus have created an urgent need for an effective vaccine should an outbreak expand to pandemic proportions.

References

  • Anthony et al. (2017). Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. Bio. 4;8(2). PMID: 28377531
  • Wang et al. (2015). Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 28;6:7712. PMID: 26218507
  • Reusken et al. (2013). Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 13(10):859-66. PMID: 23933067
  • Al-Amri et al. (2017). Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Sci Rep. 23;7:44875. PMID: 28332568
  • Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization.

MERS Coronavirus Antigens

The Native Antigen Company have produced a recombinant MERS-CoV Spike protein in our mammalian cell expression system. This protein is suitable for use in assay development, vaccine research and as antigens for the preparation of antibodies.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

7 + 11 =

Live Customer Feedback